We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 238

Public Health Groups Urge Court to Reject FDA’s Proposed Schedule for Graphic Health Warnings
  • Troutman Sanders LLP
  • USA
  • October 30 2018

Last month, the U.S. District Court for the District of Massachusetts found that FDA “unlawfully withheld” and “unreasonably delayed” the

Federal Court Forces FDA’s Hand on Graphic Warning Labels
  • Troutman Sanders LLP
  • USA
  • September 7 2018

This week, in a rare instance of a court directing a federal agency to take action, the U.S. District Court for the District of Massachusetts ordered

High Hopes and Torched Dreams
  • Burns & Levinson LLP
  • USA
  • June 27 2018

This week’s cannabis news was filled with high hopes for some and torched dreams for others. On the one hand, the Food and Drug Administration made

Recent State Court Decisions and FDA Inaction Leave Brand Name Manufacturers Uncertain About Liability for Updating Safety Labeling: The Impact of the “Sameness” Standard
  • Epstein Becker Green
  • USA
  • March 30 2018

Two cases decided over the last three months have added California and Massachusetts to the list of minority states that hold brand name

Insys Therapeutics Runs Afoul of Attorneys General in Two States
  • FisherBroyles LLP
  • USA
  • October 10 2017

Arizona-based pharmaceutical company Insys Therapeutics Inc. (Insys) has found itself under investigation in both Massachusetts and New Jersey over

Pharmacist at Center of 2012 Fungal Meningitis Outbreak Sentenced to 9 Years in Prison
  • FisherBroyles LLP
  • USA
  • June 30 2017

Earlier this year a federal court jury in Boston found the owner of a now-defunct compounding pharmacy guilty of racketeering and fraud for his role

First Circuit Rejects Whistleblower’s Fraud on the FDA FCA Theory
  • Ropes & Gray LLP
  • USA
  • January 4 2017

On December 23, 2016, the First Circuit held that a relator under the federal False Claims Act (“FCA”) failed to plausibly plead that defendant

Massachusetts Court Weighs in on Product Hopping Allegations and Reverse Payment Standing
  • McDermott Will & Emery
  • USA
  • November 11 2016

Addressing a motion to dismiss a bevy of antitrust allegations, the US District Court for the District of Massachusetts held that a class of

Massachusetts Rebuffs Latest Plaintiff Attack on Reproductive Choice
  • Reed Smith LLP
  • USA
  • October 5 2016

We’ve often thought that tort reform should be a major goal of those interested in preserving women’s reproductive choice. Every prescription

Another Rejection of Innovator Liability
  • Dechert LLP
  • USA
  • June 6 2016

It’s been a bit of a slow news week in the drug and device litigation world. We are coming off a short work week and like the rest of us, judges may